Share-based Payment Arrangement, Expense in USD of C4 Therapeutics, Inc. from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
C4 Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q3 2019 to Q3 2025.
  • C4 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $4.59M, a 48% decline year-over-year.
  • C4 Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $23.3M, a 16% decline year-over-year.
  • C4 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $29.7M, a 8.91% increase from 2023.
  • C4 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $27.2M, a 9.27% decline from 2022.
  • C4 Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $30M, a 39.5% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

C4 Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $23.3M $4.59M -$4.24M -48% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $27.6M $4.99M -$1.39M -21.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $29M $5.51M -$708K -11.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 $29.7M $8.24M +$1.88M +29.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $27.8M $8.83M +$631K +7.7% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $27.2M $6.38M -$44K -0.69% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $27.2M $6.22M -$36K -0.58% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $27.2M $6.36M -$560K -8.09% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $27.8M $8.2M +$2.19M +36.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $25.6M $6.43M -$1.72M -21.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $27.3M $6.25M -$2.69M -30.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $30M $6.92M +$566K +8.91% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $29.5M $6.01M -$75K -1.23% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $29.5M $8.15M +$2.92M +55.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $26.6M $8.94M +$5.09M +132% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $21.5M $6.35M +$3.63M +134% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-23
Q3 2021 $17.9M $6.09M +$5.65M +1296% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $12.2M $5.23M +$5.07M +3147% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $7.16M $3.85M +$3.73M +3215% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $3.43M $2.72M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 $436K -$191K -30.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $161K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $116K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q3 2019 $627K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12

C4 Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $29.7M +$2.43M +8.91% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $27.2M -$2.78M -9.27% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $30M +$8.5M +39.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 $21.5M +$18.1M +527% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-23
2020 $3.43M +$1.79M +109% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-24
2019 $1.64M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.